Drug
Everolimus
Everolimus: highest development phase Post-Market, developed by Novartis, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novartis, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Everolimus NCT02328963 | Post-Market | Transplantation Infection |
| Everolimus NCT05252585 | Post-Market | Renal Angiomyolipoma |
| Everolimus NCT01058655 | Phase 1/2 | Gastrointestinal Cancer |
Latest
No recent events.
Follow Everolimus on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.